Format
Sort by
Items per page

Send to

Choose Destination

Best matches for low dose naltrexone cancer:

Search results

Items: 1 to 20 of 41

1.

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Toljan K, Vrooman B.

Med Sci (Basel). 2018 Sep 21;6(4). pii: E82. doi: 10.3390/medsci6040082. Review.

2.

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.

Miskoff JA, Chaudhri M.

Cureus. 2018 Jul 5;10(7):e2924. doi: 10.7759/cureus.2924.

3.

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.

Li Z, You Y, Griffin N, Feng J, Shan F.

Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Review.

PMID:
29885638
4.

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.

Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.

Cochrane Database Syst Rev. 2018 Jun 5;6:CD006332. doi: 10.1002/14651858.CD006332.pub3. Review.

PMID:
29869799
5.

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment.

Weinstock LB, Brook JB, Myers TL, Goodman B.

BMJ Case Rep. 2018 Jan 11;2018. pii: bcr-2017-221405. doi: 10.1136/bcr-2017-221405.

6.
7.

Selective opioid growth factor receptor antagonists based on a stilbene isostere.

Stockdale DP, Titunick MB, Biegler JM, Reed JL, Hartung AM, Wiemer DF, McLaughlin PJ, Neighbors JD.

Bioorg Med Chem. 2017 Aug 15;25(16):4464-4474. doi: 10.1016/j.bmc.2017.06.035. Epub 2017 Jun 27.

8.

The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet].

Ringerike T, Pike E, Nevjar J, Klemp M.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Apr.

9.

Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats.

Tawfik DI, Osman AS, Tolba HM, Khattab A, Abdel-Salam LO, Kamel MM.

Neuropeptides. 2016 Oct;59:39-45. doi: 10.1016/j.npep.2016.06.003. Epub 2016 Jun 22.

PMID:
27392602
10.

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.

Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG.

Int J Oncol. 2016 Aug;49(2):793-802. doi: 10.3892/ijo.2016.3567. Epub 2016 Jun 7.

PMID:
27279602
11.

Duration of opioid receptor blockade determines biotherapeutic response.

McLaughlin PJ, Zagon IS.

Biochem Pharmacol. 2015 Oct 1;97(3):236-46. doi: 10.1016/j.bcp.2015.06.016. Epub 2015 Jun 25. Review.

PMID:
26119823
12.

Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need.

Raffaeli W, Indovina P.

Pain Med. 2015 Jun;16(6):1239-42. doi: 10.1111/pme.12704. Epub 2015 Feb 3. No abstract available.

PMID:
25643645
13.
14.

Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.

Grinnell SG, Majumdar S, Narayan A, Le Rouzic V, Ansonoff M, Pintar JE, Pasternak GW.

J Pharmacol Exp Ther. 2014 Sep;350(3):710-8. doi: 10.1124/jpet.114.213199. Epub 2014 Jun 26.

15.

Metabolic treatment of cancer: intermediate results of a prospective case series.

Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM.

Anticancer Res. 2014 Feb;34(2):973-80.

PMID:
24511042
16.

Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).

Meng J, Meng Y, Plotnikoff NP, Youkilis G, Griffin N, Shan F.

Int Immunopharmacol. 2013 Dec;17(4):1084-9.

PMID:
24455776
17.

Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.

Zagon IS, Donahue R, McLaughlin PJ.

Exp Biol Med (Maywood). 2013 May;238(5):579-87. doi: 10.1177/1535370213488483.

PMID:
23856908
18.

Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.

Parikh N, Goskonda V, Chavan A, Dillaha L.

Clin Drug Investig. 2013 Jun;33(6):391-400. doi: 10.1007/s40261-013-0079-8.

PMID:
23605506
19.

Oxycodone combined with opioid receptor antagonists: efficacy and safety.

Davis M, Goforth HW, Gamier P.

Expert Opin Drug Saf. 2013 May;12(3):389-402. doi: 10.1517/14740338.2013.783564. Epub 2013 Mar 28. Review.

PMID:
23534906
20.

Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment.

Rogosnitzky M, Finegold MJ, McLaughlin PJ, Zagon IS.

Invest New Drugs. 2013 Aug;31(4):1066-70. doi: 10.1007/s10637-012-9918-3. Epub 2012 Dec 30.

PMID:
23275062

Supplemental Content

Loading ...
Support Center